Clinical Trial: The Relationship Between Novel Virological Indicators and Treatment With Different Nucleotide Analogues and the Prognosis of HBV-ACLF Patients

U.S., Sept. 12 -- ClinicalTrials.gov registry received information related to the study (NCT07815418) titled 'The Relationship Between Novel Virological Indicators and Treatment With Different Nucleotide Analogues and the Prognosis of HBV-ACLF Patients' on Sept. 07.

Brief Summary: This is an observational study. This study mainly explores the dynamic changes of HBV RNA and HBcrAg during the treatment of HBV-ACLF, as well as the safety of entecavir (ETV), tenofovir alafenamide (TAF) and tenofovir amibufenamide (TMF) during the treatment process, and evaluates the differences in patient prognosis among the three drugs.

Study Start Date: Feb. 01, 2022

Study Type: OBSERVATIONAL

Condition: Acute-on-Chronic Liver Failure (ACLF) hepatitisB Tr...